$DGX

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.

Quest Diagnostics will offer Roche’s FDA-cleared pTau217 blood test for Alzheimer’s assessment in Q4 2026, along with its own multi-biomarker panel in 2027. The tests aim to improve diagnosis accuracy and reduce indeterminate results, aligning with Alzheimer’s Association guidelines.

Quest Diagnostics (DGX) added Humanity Health's $29 Biological Age analysis to select health profile tests on questhealth.com. Customers can access the report via Quest's 2,000 U.S. centers. The model, trained on 306,000 UK Biobank participants, estimates biological age and its contributors. Quest cannot refund third-party reports.

Quest Diagnostics (DGX) will offer Roche's FDA-cleared pTau217 blood test for Alzheimer's assessment, expanding its AD-Detect® portfolio. The test will be available Q4 2026. Quest also launches a new multi-biomarker AD-Detect test with a 10% indeterminate rate, aiming to provide more actionable insights for patients.

Quest Diagnostics (DGX) hit a 52-week high, driven by consistent earnings beats. It reported EPS of $3.12 vs. $2.81 estimate, with revenue beating consensus by 2.15%. The company has a Zacks Rank of #2 (Buy) and a VGM Score of B. DGX trades at 21.6X current fiscal year EPS estimates. Option Care Health (OPCH), a peer, also shows strong fundamentals and a Zacks Rank of #2.

McKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.

Quest Diagnostics (DGX) announced a quarterly cash dividend of $0.86 per share, payable Oct. 21, 2026, to shareholders of record Oct. 6, 2026. The stock was $236.04, down slightly over a week, with 30-day return 14.58% and YTD 35.82%. Simply Wall St estimates fair value at $245.87, citing dividend support and valuation assumptions, with risks including reimbursement and costs.

Quest Diagnostics (DGX) reported 2Q and six-month 2026 results and raised full-year revenue and earnings guidance, according to the company. The article cites DGX shares up 8.34% (1 month), 23.58% (90 days), and 37.26% (1 year). It notes a fair value estimate of $239.38 versus a $233.72 close and flags reimbursement cuts and higher wage and automation costs as risks.

Daimini Chokshi Quest Diagnostics recruits Merck executive director Daimini Chokshi to serve as VP, investor relations, based at the company’s headquarters in Secaucus. During almost two decades at Merck, Chokshi held positions including director, investor relations and director, U.S. oncology finance.

Quest Diagnostics (NYSE: DGX) and Hologic, Inc. reported a Health Trends study using deidentified molecular lab data from 1.5 million women tested at Quest from 2022-2024. BV was found in 38.7% of cases; 12.0% of BV-positive women also had at least one STI versus 3.8% of BV-negative. BV-positive status showed higher odds of chlamydia, gonorrhea, and trichomonas.